Lymphocytes were isolated from whole blood by Histopaque (Sigma) centrifugation. Cells were washed by phosphate buffered saline and then RNA was extracted by single step guanidinium thiocyanate phenol extraction.8 Alternatively, RNA was isolated from lymphocytes or lymphoblastoid cell lines by guanidinium thiocyanate lysis followed by caesium chloride centrifugation. 9 The CF cDNA sequence was divided into eight segments (A to H) as is shown in fig 1. Segments A to F broadly correspond to predicted functional domains of the protein, and segments G and H to the 3' non-coding region of the mRNA. In order to amplify the CF cDNA from lymphocyte RNA, in which the CF gene message is represented at an extremely low level, it was necessary to have two 30 to 35 cycle rounds of polymerase chain reaction (PCR) for each segment, using nested sets of primers. The primer sequences are shown in the table. The first round of PCR was carried out using primer set 1 following cDNA synthesis primed by the 3'20-mer (IL) of each PCR reaction. The second round of PCR amplification was done using primers located inside those used in the first round reaction (primer set 2). Fifty nanograms of the 3' primer for each CF gene segment was annealed to 0 5 to 1 jg of total RNA at 65'C. cDNA was synthesised from this primer with reverse transcriptase (Gibco BRL) in 50 mmol/l Tris-HCl, pH 8-5, 75 mmol/l KCI, 5 mmol/l DTT, Primer sequences used for PCR amplification of CF gene cDNA segments. In order to establish the fidelity of the 'ectopic' CF gene transcript in lymphocytes, we first attempted to detect the A F508 mutation in exon 10 in known carrier subjects. RNA from the B region of the gene sequence which includes this mutation ( fig  1) was reverse transcribed, amplified by PCR, and subjected to chemical mismatch analysis.'0 Where the PCR reaction yielded small amounts of nonspecific product, the fragment of interest was purified on agarose gels before GeneClean (Bio 101) separation. Fig 3 shows a mismatch reaction with different ratios of control to patient (A F508 carrier) DNA in the hybrid annealing step. Though with ratios of 1:10 and 1:20 control:patient DNA we were unable to detect the three base pair deletion at base 1654, when the ratio was increased to 1:30 or 1:40, mismatch bands of about 635 and 265, corresponding to the two cleavage products caused by the A F508 deletion, were clearly visible after both osmium and hydroxylamine modification. The three T residues in the mismatch are detected by the osmium tetroxide modification and a C residue adjacent to the deletion, and so destabilised, is modified by hydroxylamine. a new approach to the definition of mutations in the CF gene. We have shown that CF gene cDNA isolated by this method reliably reproduces known mutations and polymorphisms in the CF gene including the common AF508 mutation and the A1540-G polymorphism.
